Payers

Cardiometabolic screening is becoming a consumer product. Prevention is still a health-system job

Divarasib Raises the KRAS G12C Bar

Ten Years of MS Data Make Delay Harder to Defend

One Blood Test for 50 Cancers Is Closer to the FDA. The Evidence Is Still Fighting Back.

Precision Oncology Has a Scale Problem

ESR1 Resistance Is Becoming a Treatment Pathway, Not a Footnote

Life insurers are moving from pricing metabolic risk to trying to reduce it

CLL Just Moved a Noncovalent BTK Inhibitor Into First Line

Myeloma Pain May Need 4 Gy, Not a Treatment Odyssey
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
